ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Tamoxifen Makes ER-Negative Breast Cancer Easier To Find

October 31, 2008

NCI To Recompete NSABP in 1995, Chabner tells Senate

May 20, 1994

Cancer Control Seeks Grant Applications In Three Interventions Areas And In Community Development

September 13, 1974

NCI RFAs Available

May 5, 2000

In Brief: NCI’s John Czajkowski Takes Executive Dean Position At Harvard Medical School

February 21, 2014

Litton’s Government Contracts Status Under Review

September 6, 1985